# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Jason Butler reiterates Precigen (NASDAQ:PGEN) with a Market Outperform and maintains $14 price target.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a Buy and maintains $6 price t...
Stifel analyst Benjamin Burnett maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price target from $7 to $10.
– Phase 1/2 pivotal study met the primary safety and efficacy endpoints –– 51% (18 out of 35) of patients achieved Complete...
Cantor Fitzgerald analyst Jennifer Kim reiterates Precigen (NASDAQ:PGEN) with a Overweight.
Stifel analyst Benjamin Burnett maintains Precigen (NASDAQ:PGEN) with a Buy and maintains $7 price target.